MAIA Biotechnology, Inc. 10-Q

Item 5 . Other Information. None 31 Item 6 . Exhibits. The following exhibits are included, or incorporated by reference, in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (and are numbered in accordance with Item 601 of Regulation S-K). Exhibit Number Description 3.1 (1) Amended and Restated Certificate of Incorporation of MAIA Biotechnology, Inc. 3.2 (1) Amended and Restated Bylaws of MAIA Biotechnology, Inc. 10.1 (2) Sales Agreement, dated September 1, 2023, by and between MAIA Biotechnology, Inc. and ThinkEquity LLC. 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1** Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2** Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. ** These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. (1) Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on August 1, 2022. (2) Filed as an exhibit to our Current Report on Form 8-K filed with the SEC on September 1, 2023. 32 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MAIA Biotechnology Inc. Date: November 7, 2023 By: /s/ Vlad Vitoc Vlad Vitoc Chief Executive Officer (Principal Executive Officer) Date: November 7, 2023 By: /s/ Joseph McGuire Joseph McGuire Chief Financial Officer (Principal Financial Officer) 33